6533b831fe1ef96bd1299b44

RESEARCH PRODUCT

Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network

Uros MarkovicMelania CarlisiVittorio Del FabroEmilia CotziaClotilde CangialosiAnxur MerendaBruno GaribaldiValeria CalafioreFrancesco AcquavivaMarina ParisiAlessandra RomanoRenato ScaloneSalvatore LeottaSanto NeriMassimo PoidomaniConcetta ConticelloGiuseppe SapienzaDonato ManninaVanessa InnaoValerio LeottaDaniele TibulloMaurizio MussoCinzia MaugeriGiovanni CardinaleEnrica Antonia MartinoGiuseppe LongoFrancesco Di RaimondoGiuseppina Uccello

subject

Oncologymedicine.medical_specialtySalvage therapylcsh:MedicineContext (language use)Article03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicinesalvage therapyKRd regimen; multiple myeloma; salvage therapyMultiple myelomaLenalidomideCumulative dosebusiness.industrylcsh:RGeneral Medicinemedicine.diseaseCarfilzomibKRd regimenClinical trialmultiple myelomaTolerabilitychemistry030220 oncology & carcinogenesisbusiness030215 immunologymedicine.drug

description

Background: The ASPIRE (NCT01080391) phase 3 trial showed the efficacy of carfilzomib, lenalidomide and dexamethasone (KRd) triplet for relapse and refractory multiple myeloma (RRMM). However, little is known about safety and efficacy of KRd outside a clinical trial context. Methods: Herein we report real life results of KRd given to 130 RRMM patients from 12 Sicilian Centers. Results: Median age was 62 years

yearjournalcountryeditionlanguage
2019-06-01
10.3390/jcm8060877https://hdl.handle.net/20.500.11769/542305